Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (1964)	7/7/1998 6:16:00 PM
From: Linda Kaplan	Respond to of 2553

Thanks, V1. Haven't seen you in a while. That's very exciting news. Is this a brand new application for our technology? Linda

To: Vector1 who wrote (1964)	7/7/1998 7:25:00 PM
From: bluejeans	Read Replies (1) \| Respond to of 2553

Thanks Vector1, I was able to watch the story thanks to your alert. Even though the stock has performed poorly as an investment, stories like this are the reason I support biotechs. Bob

To: Vector1 who wrote (1964)	7/8/1998 11:17:00 PM
From: Machaon	Read Replies (2) \| Respond to of 2553

It'll be interesting to see how significantly GENZL's Fast Track Epicel program, effects the growth rate. It used to take 23-24 days to grow an Epicel skin graft. It now takes 16 days, or just over two weeks. With burn victims, time is critical. I wonder how this significant improvement in the speed of GENZL's Epicel product will effect sales? It would also be great if this improves the treatment and prognosis for burn victims, who's injuries are very painful and difficult to treat. Good luck, Bob